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Abstract: In recent years, tremendous progress has been made in the treatment of acute 
myocardial infarction (AMI), but pathological ventricular remodeling often causes survivors 
to suffer from fatal heart failure. Currently, there is no effective therapy to attenuate 
ventricular remodeling. Recently, nanoparticles-based drug delivery system is widely applied 
in biomedicine especially in cancer and liver fibrosis, owing to its excellent physical, 
chemical, and biological properties. Therefore, using nanoparticles as delivery vehicles of 
small molecules, polypeptides, etc to improve post-infarct ventricular remodeling are 
expected. In this review, we summarized the updated researches in this fast-growing area and 
suggested further works needed. 
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Introduction 
 
With an aging population and the rising incidence of cardiovascular diseases such as 
hypertension and coronary heart disease, the prevalence of heart failure is gradually 
increasing. In 2013, 1 in 9 death certificates (284,388 deaths) in the United States mentioned 
heart failure, with heart failure being the primary cause in 58,309 of those deaths [1]. In China, 
the prevalence of heart failure is around 0.9%, and coronary heart disease is the major cause. 
 
Primary myocardial damage (including ischemic myocardial damage like myocardial 
infarction, and immune myocardium damage like myocarditis) and cardiac overload 
(including pressure overload and volume overload) can impair heart muscle, resulting in 
compensatory changes such as ventricular hypertrophy or ventricular enlargement, known as 
“ventricular remodeling”. In this process, the heart's geometry, cardiomyocytes, interstitial 
components, and the phenotype of cardiomyocytes undergo a series of pathological changes. 
Ventricular remodeling is the basic mechanism of heart failure and has three main 
characteristics: 1) pathological cardiomyocyte hypertrophy accompanied by re-expression of 
embryonic genes; 2) myocytes death; 3) excessive fibrosis or increased degradation of 
myocardial extracellular matrix. In recent years, the molecular mechanism of ventricular 
remodeling has been studied mainly from the following aspects: (1) myocardial hypertrophy; 
(2) fibrosis; (3) inflammation; (4) mitochondrial dysfunction; (5) autophagy/apoptosis. We 
may slow the progression of cardiac remodeling by targeting the above mechanisms, thus 
benefiting heart failure patients. 
 
Nanoparticles refer to particles smaller than 100nm in at least one dimension. Due to its small 
size and excellent thermal and electrical properties, nanoparticles are now widely applied into 
biomedical and industrial fields such as aerospace, electronics, cosmetics, food additives and 
optical devices [2]. Meanwhile, considering inherent nanometer size of living cells’ biological 
components, nanotechnology is being considered in various medical fields such as oncology 
and cardiovascular medicine. Nanoparticles as delivery vehicles of proteins, nucleic acid and 
small molecules may potentially provide sustained treatment in damaged tissues. Basic 
research showed that nanoparticles packed with Nox2-NADPH oxidase siRNA, insulin 
growth factor-1 (IGF-1), or pitavastatin enhanced cardiac function post MI [2-4], suggesting 
the infinite possibilities of nanoparticles in the treatment of post-infarct ventricular 
remodeling. 
 
In this review, we first introduced the present understanding of mechanism of ventricular 
remodeling and new advances of drugs for ventricular remodeling, then focused on the most 
commonly used nanoparticles in cardiovascular disease, especially for post-infarct ventricular 
remodeling. We also briefly touched on nanoparticles used as diagnostics/biomarkers for 
cardiovascular disease, and engineering of nanoparticles for tailored and directed use, which 
are both growing rapidly in the area. 
 
1. The mechanism of ventricular remodeling 
 
1.1 myocardial hypertrophy 
Myocardial hypertrophy is a powerful adaptive form for various causes of cardiac output 
reduction, but it is not infinite. If pathological factors last for a long time, the function of the 
hypertrophic myocardium cannot be maintained persistently and eventually turns to heart 
failure. At present, plenty of studies support that APJ receptor plays a significant part in 
cardiac hypertrophy [5]. The hypothesis has been raised that APJ internalization via 
clathrin-mediated endocytic pathway may contribute to myocardial hypertrophy. As the 
molecular mechanisms of cardiac hypertrophy have been widely studied，the role of long 
non-coding RNAs (lncRNAs) has become more prominent [6]. The lncRNA Mhrt (myosin 
heavy chain-associated RNA transcript) is shown to affect cardiac hypertrophy remodeling by 
affecting the acetylation of myocardin, a substance which is necessary for programming 
cardiac muscle [7]. 
 
1.2 Myocardial fibrosis 
Myocardial fibrosis is known for excessive accumulation of extracellular matrix in the 
myocardium, which a basic component for most cardiac pathologic changes [8]. Fibrotic 
cardiac muscle is stiffer and less compliant, causing ventricular systolic and diastolic 
dysfunction. 
 1.2.1 Changes in extracellular matrix components (ECM)   
Myocardial extracellular matrix is composed of collagen, proteoglycans, glycoproteins, 
glycosaminoglycans, and elastic fibres, which are synthesized and secreted by cardiac 
fibroblasts. These components are essential for the nutrition and conduction of myocardium, 
and the normal structure and function of heart. Under the condition of ischemia and hypoxia, 
cardiac fibroblasts will move to the injured site, and produce a large amount of extracellular 
matrix under the mediation of various cytokines and neurohumoral factors. 
Epicardium-derived cells, but not bone marrow-derived blood cells, are the main origin of 
cardiac fibroblasts in the infarcted heart [9]. Significantly, differentiated states of fibroblasts 
are of importance to post-infarct ventricular remodeling of scarring. Fibroblasts were 
activated and highly proliferative, reaching a maximum rate within 2 to 4 days after MI. Up to 
3 to 7 days, these cells differentiated into myofibroblasts and expressed smooth muscle α
-actin to structurally construct the infarcted zone. As the scar completely formed (around 7-10 
days), myofibroblasts gradually lost proliferative ability and smooth muscle α -actin 
expression [10]. This suggests that these fibroblasts might be a target of 
nanoparticle-mediated drug delivery system.   
 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases which can 
degrade ECM. According to their structure and substrate selectivity, MMPs can be roughly 
classified into collagenase, gelatinase, matrix lysin, membrane-type metalloproteinase and 
others. Under normal conditions, MMPs are mostly in the form of zymogens, with low 
expression levels and weak activity. Once activated under the stimuli of various pathological 
factors, such as ischemia and hypoxia, MMPs rapidly participate in the degradation of ECM 
and modulate the signaling pathways related to vascular remodeling and myocardial fibrosis. 
It has been shown that elevated MMP-9 levels are associated with left ventricular dysfunction 
and targeted knockout of mouse MMP-9 gene can decrease collagen accumulation post MI 
and attenuate left ventricular dilation [11]. 
 
1.2.2 Disproportionality of myocardial collagen fibre   
Fibrillar collagen is the major structural protein of cardiac extracellular matrix. It is generally 
classified into type I (approximately 85%), type III (about 11%), and quite less abundant types 
IV, V and VI. Collagen types I and III have their own functions, that is collagen type I is 
responsible for building thick fibres which maintain its tensile strength, while collagen type 
III is in charge of constructing thin fibres which keep elasticity of the matrix [12]. Changes in 
the number, distribution, and arrangement of collagen fibers can lead to fibrosis. Cardiac 
fibroblasts are the major source of collagen fibers in the myocardial infarction. As the most 
frequently used marker of myocardial fibrosis, collagen peptides can predict cardiac function. 
For instance, the most common marker of type I collagen is a 100 kDa, C-terminal 
polypeptide whose plasma levels are positively correlated with diastolic dysfunction; the most 
commonly used marker for the synthesis of type III collagen is a 42-kDa, N-terminal 
polypeptide, whose plasma levels are positively associated with mortality and heart failure 
[13, 14]. 
 
1.3 Inflammation 
Inflammation plays a vital role in ventricular remodeling, and its lasting activation may result 
in irreversible cardiac damage. Activation of multiple inflammatory factors and signaling 
pathways have been mentioned in patients with heart failure [15]. Inflammatory molecules 
involved in ventricular remodeling mainly include TNF-α, IL-6, IL-10, IL-18 and nuclear 
factor-κB. Under the chemotaxis of multiple cytokines, monocytes are recruited to the cardiac 
tissue from circulation, and then they differentiate into macrophages and contribute to tissue 
injury and myocardial fibrosis [16]. Infarct macrophages exhibit inflammatory “M1” 
phenotype early and reparative“M2”phenotype later after MI [17]. Numerous studies have 
shown that the shift from M1 to M2 macrophages can improve post-infarct ventricular 
remodeling. Future studies can be aimed at targeting specific harmful functions while 
preserving beneficial effects of macrophages to prevent adverse cardiac remodeling. 
 
NLRP3 inflammasome is a large molecule polyprotein complex, a component of the innate 
immune system. It is of great importance in both aseptic and infectious inflammation and can 
be activated by a variety of endogenous and exogenous factors. Studies have revealed that 
NLRP3 is closely associated with the pathogenesis of heart failure. When the myocardium is 
in a state of ischemia, NLRP3 is activated, producing IL-1β and IL-18. IL-1β further activates 
nuclear transcription factor (NF-κB). In turn, activation of NF-κB can also induce the 
expression of precursors such as IL-18 and IL-1β. IL-18 is associated with the expression of 
collagen types I and III in a dose-dependent manner and induces myocardial remodeling and 
interstitial fibrosis. 
 
1.4 Mitochondrial dysfunction 
Mitochondrial dysfunction may potentially participate in almost all the mechanisms involved 
in ventricular remodeling [18]. Varieties of studies have demonstrated that there are functional 
defects of electron transport chain and oxidative phosphorylation complex in myocardial 
mitochondria during heart failure. In animal models of heart failure, the activity of myocardial 
mitochondrial complex IV is significantly reduced and the activity of complex I and III are 
inhibited. These changes not only reduce mitochondrial ATP synthesis but also increase 
mitochondrial ROS production. ROS modifies the myofibrillar protein of the myocardium 
through oxidation, resulting in the progressive reduction of cardiac contractility and 
irreversible cardiac damage [19]. 
 
In addition, angiotensin II (Ang II) destroys myocardial mitochondria by increasing the 
production of reactive oxygen species (ROS) and interferes with mitochondrial oxidative 
phosphorylation, including fatty acid oxidation [18, 20]. Fatty acids are the main energy 
substrate of the heart and offer most cofactors essential for mitochondrial oxidative 
phosphorylation. Studies have shown that overexpression of angiotensinogen in transgenic 
mice (TG1306/R1 mice) can reduce cardiac fatty acid oxidation and expression of PPARα 
protein and fatty acid oxidase [21]. 
 
1.5 Autophagy and Apoptosis 
Autophagy is the decomposition process of proteins and organelles. It is characterized by the 
encapsulation of cytoplasmic proteins or organelles to form autophagosomes with a bilayer 
membrane structure. Autophagosomes fuse with lysosomes to form autolysosomes. The 
parcels are decomposed into small molecules such as free amino acids and fatty acids and be 
recycled [22]. Macroautophagy, microautophagy, and chaperon-mediated autophagy all allude 
to autophagy, but here autophagy refers to macroautophagy [23]. Cardiomyocyte autophagy 
plays a prominent role in maintaining the stability of internal environment, and the structure 
and function of heart. Ischemia induces autophagy in cardiomyocytes. Kanamori first reported 
that autophagy was rapidly activated in cardiomyocytes within 30 minutes after coronary 
ligation, and strong autophagic activity was observed particularly in saved cardiomyocytes 
around the infarcted zone [24]. His following study found that autophagy inhibitor 
chloroquine can reduce myocardial autophagy and aggravate ventricular dilatation and 
myocardial remodeling, suggesting that autophagy plays a protective role in post-infarct 
ventricular remodeling [25]. There are two main pathways for the regulation of myocardial 
cell autophagy: 1) mTOR-dependent pathway; 2) Beclinl-dependent pathway. Among them, 
the mTOR-dependent pathway plays a major role in post-infarct ventricular remodeling. 
mTOR,a serine/threonine protein kinase, is proved to regulate autophagy. Increased mTOR 
activity inhibits autophagy, while decreased mTOR activity activates autophagy [26]. 
 Necrosis has been considered as the only cause of myocyte loss in MI for a long time. 
However, mounting evidence suggests that apoptosis plays a critical role in the progression of 
post-infarct ventricular remodeling and heart failure, too．Cardiac-specific caspase-3 is the 
most important caspase in the terminal apoptotic pathway in the infarcted heart. The study 
found that overexpression of caspase-3 increased infarct size in transgenic mice [27]. Vice 
versa, reduced caspase-3 narrowed the infarct size, lowered the number of apoptotic 
cardiomyocytes and promoted the cardiac function in MI mice [28, 29]. One study from Zhou 
et al. found that isoproterenol induces abnormal endoplasmic reticulum stress through 
inactivation of AMPK, which in turn damages cardiomyocytes, causes apoptosis, and leads to 
heart failure in rats, and all the processes can be suppressed by activating AMPK, providing a 
potential mechanism of apoptosis [30].  
 
In conclusion, none of the above processes is independent. On the contrary, they interact with 
each other and form a complex mechanism network. Nanoparticles loaded with the drugs 
targeting any of these mechanisms are expected to reverse ventricular remodeling and prevent 
further progression of the disease. We summarized the mechanism of ventricular remodeling 
in Figure 1. 
 
  
2. Nano- cargo for ventricular remodeling  
 
Drugs, proteins, RNA and other small molecules all can be the cargo of nanoparticle-based 
drug delivery system, which we describe below in details. 
 
2.1 Drugs 
We summarized new advances of drugs for ventricular remodeling in Table 1. The recent 
development of cardiovascular medicine and coronary intervention like PCI greatly decreased 
the mortality of AMI, but the incidence of chronic heart failure patient’s post MI is increasing. 
Nanotechnology-based drug delivery system (nano-DDS) is a hot topic in drug delivery and 
has been successfully adopted in cancer therapy. Besides higher biocompatibility, Nano-DDS 
can increase the precision of drug targeting and the level of drug accumulation in the desired 
area, which will be discussed in detail in later sections. Therefore, nano-DDS has great 
potential in cardiovascular diseases. As is known to us all, statins have anti-inflammatory 
effects. Shunsuke Katsuki et al utilized PLGA as the carrier of Pitavastatin and tested its 
efficacy in MI model. They found intravenous treatment with PLGA-Pitavastatin 
nanoparticles attenuated post-infarct ventricular remodeling by interfering with monocyte 
recruitment and reducing monocyte/macrophage accumulation in the heart. This indicated that 
inflammatory cells might be the target of PLGA-Pitavastatin nanoparticles [31]. 
 
However, not all the drugs can be nanoparticulated in view of size and structure. Furthermore, 
there are few animal studies using nanoparticles in the treatment of heart diseases, albeit 
clinical trials. For example, Zhang, et al showed size-dependent cardiac effects of gold 
nanoparticles in isoproterenol-induced hyperthyroid rats, suggesting that size is an important 
factor affecting safety and efficacy of nano-DDS [32]. Further extensive work is needed to 
explore the target cells and examine the efficacy and safety of these cardioprotective drugs 
with nano-DDS before going into clinical trials.  
 
Table1. New advances of drugs for ventricular remodeling 
Classification Typical Drugs Function References 
Renin-Angiotensin-A
ldosterone System 
(RAAS) Inhibitors 
 
Aliskiren, Aldosterone, 
Eplerenone 
 
Inhibit cardiac hypertrophy and reduce the 
proliferation of extracellular matrix and 
interstitial fibrosis. 
Gheorghiade M, et al 
[33] 
Dhillon S, et al [34] 
β-Adrenoceptor 
Blockers 
Atenolol, Metoprolol 
Tartrate Tablets , 
Propranolol 
 
Block the sympathetic nervous system, 
RAAS system and reduce oxygen 
consumption of heart muscle. 
Xie M, et al [35] 
Hydroxy-3-methyl-gl
utaryl Coenzyme A 
(HMG-CoA) 
Inhibitors  
Atorvastatin、rosuvastatin 
 
 
Inhibit oxidation and inflammation, reduce 
sympathetic nerve activity, and improve 
vascular endothelial function. 
Duan H Y, et al [36] 
Mahalwar R, et al [37] 
Vascular 
Endothelin-1 (ET-1) 
Receptor Antagonists 
Bosenta, Enrasentan, 
Tezosent, Sitaxentan, 
Atrasentan, Ambrisentan 
 
Contract blood vessels, promote cell 
mitosis and proliferation. 
Prasad S K, et al [38] 
New vasodilators Sildenafil,AVE9488 Inhibit cardiac hypertrophy, apoptosis and 
fibrosis 
Vecchis R, et al [39] 
Fraccarollo D, et al 
[40] 
 
2.2 Proteins 
We summarized some proteins which contribute to cardiac repair and attenuate adverse 
remodeling in Table 2. Under ischemic conditions, certain proteins can play important roles in 
attenuating and delaying pathological ventricular remodeling. However, their effect is quite 
limited as a result of short half-lives in vivo in their free form. What if they are 
nanoparticulated? In fact, some of them have been nanoparticulated for use in the treatment of 
post-infarct ventricular remodeling in animal experiments. For example, injecting 
PLGA-IGF-1 nanoparticles into the myocardium of MI mice was effective to narrow infarct 
size, prevent cardiomyocyte apoptosis, and improve left ventricle ejection fraction three 
weeks after the left coronary ligation surgery [3]. But similar animal studies are still lack, and 
transition from basic research into clinical trials is near to zero. Future studies should focus on 
this part of works and provide more reliable data. 
 
Table 2. New advances of proteins for ventricular remodeling 
Proteins Cardioprotective effect References 
 Vascular endothelial growth factor 
(VEGF) 
 Promote cardiac stem cells differentiation into 
vascular endothelial cells. 
Xiao N, et al [41] 
Insulin-like growth factor-1 
(IGF-1 ) 
Promote stem cell growth and differentiation. Jackson R, et al [42] 
Thymosin β4 Promote neoangiogenesis and cardiac 
regeneration. 
Srivastava D, et al [43] 
Shrivastava S, et al [44] 
Fibroblast activation protein 
alpha(FAP) 
Promote fibroblast migration Tillmanns J, et al [45] 
Hypoxia-inducible factor-1 alpha 
(HIF-1α) 
Promote cardiac function, angiogenesis, 
cardiomyocyte proliferation, and reduction of 
fibrotic tissue with no induction of cardiac 
hypertrophy. 
Cerrada I, et al [46] 
Wnt1/βcatenin Induces cardiac fibroblasts to proliferate and 
express pro-fibrotic genes. 
Duan J, et al [47] 
Transforming growth factor-β(TGF-β)  Activate a pro-fibrotic and matrix-preserving 
program in infarct fibroblasts through 
Smad-dependent actions. 
 Shinde AV, et al [48] 
 
2.3 RNA 
MicroRNAs (miRNAs) are small, noncoding, single-stranded RNAs, which can regulate the 
gene expression by interacting with target mRNAs and preventing them translating into 
functional proteins. It has been shown that miR-1, miR-21, miR145, etc modulated the gene 
expression relative to ventricular remodeling. If these miRNAs are nanoparticulted and 
delivered to the infarcted heart, it may prevent adverse ventricular remodeling. In fact, 
extracellular vesicles are natural delivery vehicles of miRNA and have been used in the 
treatment of ventricular remodeling in basic research, which will be discussed in detail in later 
part. Other kinds of nanoparticles such as liposomes are also studied. For example, one study 
investigated that miR-145 encapsulated in liposomes was intravenously administered to MI 
rabbit and had a cardioprotective effect by inducing cardiomyocyte autophagy through 
targeting fibroblast growth factor receptor substrate 2 [49]. 
 
Small hairpin RNA (shRNA), an artificial RNA, is named for a tight hairpin turn that can be 
used to silence specific gene expression through RNA interference (RNAi) and reduce the 
level of targeted proteins. As an example, one study exhibited that rPEI/siRAGE showed high 
target gene silencing and low toxicity in cardiomyocytes, and the treatment of rPEI/siRAGE 
reduced the myocardial infarction size [50]. 
 
3. Nanoparticles for treatment of post-infarct ventricular remodeling 
 
Heart failure post MI is an important component of cardiovascular related diseases. As 
mentioned before, the repair mechanism of post MI causes collagen scarring to replace 
damaged cardiomyocytes. The non-shrinkage of the scar leads to viable cardiac hypertrophy, 
thinning of the infarct wall and expansion of the ventricles, which is known as ventricular 
remodeling. Without effective treatment, these processes will continue until the heart no 
longer adequately pumps enough blood to the body, which is defined as heart failure. At 
present, the drugs used for the treatment of heart failure only aim at its pathophysiological 
process, but do not target the cause. Worse still, the current available means of delivering 
cardioprotective drugs often misses the deadline of reversible repair of cardiomyocytes and 
inevitably, cardiomyocytes undergo a series of remodeling processes. Therefore, developing 
novel therapies to alleviate the negative left ventricular remodeling post MI is very important.   
 
Nanoparticles refer to nanometer-sized particles. It is defined as particles smaller than 100 nm 
in at least one dimension. Due to its small size and excellent thermal and electrical properties, 
nanoparticles are now widely used in industrial and biomedical fields such as cosmetics, food 
additives, aerospace, electronics, and optical devices [2]. Considering the intrinsic nanometer 
size of the living cell's biological components, if nanoparticles are designed as delivery 
vehicles of a variety of growth factors, enzymes and small molecule, the modified 
nanoparticles may provide infinite possibilities in the treatment of cardiovascular diseases. In 
addition, nanoparticles can achieve controlled drug release by constructing a release system in 
response of internal stimuli such as pH, redox state and the presence of biomolecules as well 
as external stimuli such as light and magnetic field. One study showed that pH-sensitive 
mesoporous silica based nanoparticles (MSN) could be mostly taken up by tumor cells for 
their acidic environment due to hypoxia [51]. Similarly, an infarcted heart is also in an acidic 
environment under ischemic condition. pH-sensitive nanoparticles can also be designed to 
achieve controlled drug release. In addition, if the nanoparticles can only be opened by 
specific enzyme which is limited to infarct heart, the controlled drug release can also be 
achieved. Currently, the most commonly used nanoparticles in cardiovascular research are 
inorganic nanoparticles, liposomes, and extracellular vesicles, which are discussed below.  
 
3.1 Inorganic nanoparticles 
Common inorganic nanoparticles include gold nanoparticles, silver nanoparticles, and silicon 
nanoparticles and so on. They are widely studied in basic research associated with 
cardiovascular diseases. 
 
3.1.1 Gold nanoparticles 
Gold nanoparticles (AuNPs) have great potential in the diagnosis and treatment of various 
diseases, owing to their superior physicochemical and pharmacological characters. In terms of 
physicochemical properties, AuNPs are inert, stable and biocompatible, which means low 
toxicity. Moreover, the surface of AuNPs can be retouched as we wish, to improve precision 
and safety of its application in clinical or research [52]. As for the preparation process, AuNPs 
are easy to prepare and functionalize, which may lower the production cost, and this obvious 
economic advantage will make them more available in clinical. Based on the above, AuNPs 
are a valuable candidate for many biomedical applications, such as drug delivery, cancer 
therapy and biomedical imaging. This part focuses on the previous studies of gold 
nanoparticles in drug delivery. One study showed that continuous injection of gold nanofibres 
combined with platelet-derived growth factor into the heart of rats could reduce myocardial 
cell death and maintain systolic function post MI. Considering that heart failure is related to 
abnormal electrical function, modified nanofibers to couple the electrical property was studied. 
The result showed that ex-vivo pretreatment of mesenchymal stem cells (MSCs) using 
5-azacytidine and AuNPs loaded with conductive nanofibrous construct could improve 
cardiomyogenic differentiation, thus resulting in protective effects on infarcted area [53]. 
Another study showed that PEG-coated AuNPs could attenuate β-adrenergic 
receptor-mediated acute cardiac hypertrophy and inflammation by inhibiting the expression of 
β1-AR and its downstream effectors IL-6 and ERK1/2 [52]. In conclusion, AuNPs have at 
least two functions for treating heart failure: one is used as drug vector, the other is used as 
anti-cardiac hypertrophy agents. 
 
3.1.2 Silicon nanoparticles 
Silicon nanoparticles are also drawing more and more attention. Porous silicon (Psi) shares 
the similar characters with gold nanoparticles such as nanoscale size, large surface area (>300 
m2/g) and good biocompatibility and biodegradability [54, 55]. Besides, high degree of 
porosity (50-80%) and the unique chemical surface are two special features of Psi, which can 
promote the solubility of hydrophobic drugs and control the drug release. An in vivo 
experiment tested the biocompatibility of different sizes of thermally oxidised porous silicon 
(TOPSi) nanoparticles in the heart tissue. Obvious changes in cardiac function and other 
systems like the haematological system were not found before and after MI, demonstrating 
that TOPSi nanoparticles have good biocompatibility [56]. Other research concluded that 
functionalized undecylenic acid thermally-carbonised porous silicon nanoparticles can 
improve their ability of accumulation in different cardiomyocytes (primary cardiomyocytes, 
non-cardiomyocytes, and H9C2 myocardium). It has also been reported that intravenous 
administration of peptide-modified nanoparticles in MI rats induced by isoproterenol, could 
increase the accumulation of nanoparticles in the heart up to 3.0 times at 10 minutes, 
revealing the potential therapeutic effect of these peptide-modified nanosystems in 
post-infarct ventricular remodeling. Therefore, we can confidently expect that the PSi 
materials modified with heart-targeting peptides and cardioprotective factors might serve as a 
promising approach to treating heart diseases. 
 
Nanoparticles mentioned above are delivered by directly injecting into the infarcted heart or 
through the intravenous administration. Some studies also deliver nanoparticles orally.  
However, this route of administration can cause an undesirable systemic response for their 
inherent metabolic pathways. Currently, drug delivery using inhaled nanoparticles has 
demonstrated a promising future [57-59]. For example, inhalation of calcium phosphate 
nanoparticles (CaPs) bound to peptides targeting heart were investigated and no changes in 
blood pressure, heart rate, or respiratory function were observed [58]. Therefore, efforts to 
develop tailored approaches with engineering designs are a hot topic in the study, as described 
in below part 5. 
 
It is worth noting that inorganic nanoparticles can also cause toxic effects in multiple organs. 
Experiments conducted on murine macrophage cell lines have shown that AuNPs could affect 
the immune system. In this study, AuNPs successfully reduced activation of Toll-like 
Receptors-9 receptors, which in turn reduced the secretion of various interleukins (IL-6, IL-12) 
and TNF-α [60]. Silica nanoparticles can cause toxic effects, too. The elevated level of 
pro-inflammatory cytokines like IL-6 and IL-12 , increased inflammatory cells such as natural 
killer(NK) cells and cytotoxic T-cells, and up-regulated genes associated with inflammatory 
responses were observed when cells were exposed to silica nanoparticles [61]. Besides, the 
level of cTnT, a sensitive indicator of AMI, was significantly elevated in old rats exposed to 
aerosol of silica nanoparticles [62], which exhibited cardiotoxicity. 
 
3.2 Liposomes 
Liposomes are composed of single or multiple outer lipid bilayers and an inner aqueous 
compartment, thus endowed with special properties that can be combined with both 
hydrophobic and hydrophilic materials. The diameter of liposomes is usually 20 nm to 10 μm, 
and the thickness of phospholipid bilayer is around 4-5 nm. Microfluidic technology has 
gradually been employed for liposome preparation in place of conventional methods [63-65]. 
At present, PLA, PGA and PLGA are three popular materials for the preparation of liposomes. 
Initially, liposomes were used in surgical implants and tissue repair. They were then rapidly 
introduced into other medical fields such as abdominal mesh and drug delivery vectors due to 
their excellent biocompatible, biodegradable and nontoxic properties [66-68]. Another unique 
advantage of using PLA to make nanoparticles is flexibility. Its physical properties as well as 
chemical properties are easily changed to obtain the desired pharmacokinetics and 
biodegradable properties [68, 69]. Nano-liposomes have been shown to transport many 
substances such as low molecular weight drugs, imaging agents, peptides, proteins and 
nucleic acids. They can slowly release the encapsulated drug, maintain a higher drug 
concentration in the target area, and increase drug efficacy. This ability can also be applied to 
delivery of cardioprotective agents to the infarcted heart.  
 
3.2.1 RNA 
Nox2-NADPH, the major source of ROS in the heart, is associated with ventricular 
remodeling. It has been reported that the expression of Nox2-NADPH is up-regulated in the 
infarcted myocardium and deleting the gene of Nox2 can reduce oxidative stress and prevent 
adverse post-infarct remodeling. Considered above, a study used acid-degradable polyketal 
particles as delivery vehicles for Nox2-siRNA and found that intramyocardial injection of 
Nox2-siRNA nanoparticles to the post-MI heart successfully prevented upregulation of Nox2 
and dramatically improved cardiac function [2]. 
 
3.2.2 Proteins and peptides 
A study reported that the amount of angiotensin II type 1(AT1) nano-liposomes clustered in 
the infarcted heart after day 1 accounted for almost half of the total amount accumulated in all 
organs, exhibiting superior cardiac-targeted capability [70]. IGF-1 (insulin-like growth 
factor-1), a kind of peptide, has been revealed to improving cardiomyocyte growth and 
survival both in vitro and in vivo. An animal experiment showed that injecting PLGA-IGF-1 
NPs into the myocardium of MI mice was effective in narrowing infarct size, preventing 
cardiomyocyte apoptosis, and improving left ventricle ejection fraction three weeks after the 
surgery [3].  
 
3.2.3 Drugs 
It’s well known that inflammatory responses plays a critical role in the development of 
post-infarct remodeling [71]. For this reason, a study explored the effects of PLGA NPs 
combined with the anti-inflammatory drug-pitavastatin on post-MI mice and concluded that 
treatment with PLGA-Pitavastatin NPs alleviated post-infarct remodeling along with a 
reduction of monocytes/macrophages in the heart, yet the control group did not. Specifically, 
PLGA-Pitavastatin NPs not only prevented monocytes from mobilizing in the spleen in MI 
mice, but also decreased the amount of inflammatory cells in the infarcted heart in 
splenectomy mice4. This suggests that nanoparticles loaded with pitavastatin or other similar 
drugs may be a novel therapeutic strategy to protect the heart from inflammatory damage. 
 
Compared with inorganic nanoparticles, there are few reports about the toxicity of liposomes. 
Lutein- PLGA nanoparticles were prepared and tested for acute, subacute toxicity, 
bioavailability and tissue distribution in mice. The results did not show any significant 
changes in mortality, hematology and other vital organs compared with the control group [72]. 
However long-term toxicity studies are needed. 
 3.3 Extracellular vesicles (EVs) 
Extracellular vesicles which are of nanoscale size and surrounded by a phospholipid bilayer, 
are secreted by almost all cell types into extracellular space. EVs are originally considered as 
cellular debris, but more value in carrying and exchanging biological information is explored 
with the in-depth research. According to the vesicles’ size, biogenesis and surface markers, 
EVs can generally be divided into exosomes, microvesicles/ectosomes and apoptotic bodies. 
Exosomes, roughly 30 to 100 nm in size, are derived from late endosomes. Microvesicles, 
ranging between 100 and 1000 nm, are generated by budding from the plasma membrane. 
Apoptotic bodies are derived from apoptotic cells and are more than 1000nm in diameter. 
However, due to the different methods of isolating and purifying vesicles, it is difficult to 
classify EV precisely. Clinical applications of EVs fall into two main categories: 1) EVs are 
used as biological drugs. Some of the molecules contained in EVs secreted by specific cells 
have therapeutic effects such as immunosuppression, immune activation, tissue repair and 
cardiac protection [73]. 2) EVs are used as the drug-delivery system. EVs can serve as a 
natural nano drug delivery system to deliver drugs to target cells. Currently, EVs have been 
used successfully as a carrier for the delivery of small molecules, siRNAs, proteins, and 
mRNAs for preclinical studies.     
 
One study surprisingly found that although there are many kinds of cells in the heart tissue 
such as cardiomyocytes, endothelial cells and fibroblasts, EVs from CD34+ stem cells were 
only selectively captured by cardiomyocytes and endothelial cells, indicating the existence of 
cell-specific receptors on EVs from CD34+ stem cells [74]. Increasing evidence has 
confirmed that EVs are enriched in microRNAs which regulate growth, proliferation and 
survival. More interestingly, microRNAs enclosed in different EVs are quite different from 
each other and perform different tasks. It has been demonstrated that cardiac progenitor cell 
-derived exosomal particles which contain miR-21 could prevent cardiomyocytes apoptosis 
[75]. Other similar studies investigated that miR-132 containing exosomes derived from 
pericyte had a pro-angiogenic capacity and miR-155 containing exosomes could mediate 
macrophage-fibroblast interactions and protect damaged myocytes by inhibiting fibroblast 
proliferation [76]. All of these highlight that understanding how EVs are released and taken 
up would help to manage and govern post-infarct ventricular remodeling. Future studies 
might aim at targeted delivery of EVs containing beneficial factors to heart. We summarized 
the latest findings of exosomes and their miRNAs on cardiac repair in Table 3. 
 
Table 3. Exosomes and the miRNAs on cardiac repair 
Cellular origins of exosomes Contained 
miRNAs 
Mechanism Cardioprotective 
Function 
References 
Cardiac-derived progenitor cells miR-1 Target and inhibit the 
expression of 
sprouty-related 
EVH1 
domain-containing 
protein 1 (Spred1). 
 
Enhance 
angiogenesis and 
potentially improve 
cardiac 
regeneration 
 
van Mil A, 
et al [77] 
Induced pluripotent stem cells 
(iPS cells), derived from somatic 
cells reprogrammed by four 
miR-21, 
miR -210 
Associate with 
Nanog, an embryonic 
stem cell-specific 
Reduce oxidative 
stress and promote 
cardiomyocytes 
Y Wang, et 
al [78] 
stem cell transcription factors, 
Oct4, Sox2, Klf4, and c-Myc 
transcription factor, 
and the key hypoxia 
related transcription 
factor HIF-1α. 
 
survival 
 
 
 
mesenchymal stem cells (MSC) 
overexpressing GATA-4  
 
miR-19a, 
miR-451 
Activate the Akt and 
ERK signaling 
Pathways. 
 
Reduce apoptosis Bin Yu, et al 
[79] 
human CD34
+
 peripheral 
blood-derived hematopoietic 
stem cells 
 
miR-126, 
miR-130a 
Increase production 
of CXCL12 in 
endothelial cells and 
reduce protein levels 
of phosphoinositol-3 
kinase regulatory 
subunit 2 (PIK3R2) 
Promote 
angiogenesis 
Mocharla P, 
et al [80] 
Mesenchymal stem cells miR-22 Target methyl CpG 
binding protein 2 
(Mecp2). 
 
Reduce apoptosis 
and cardiac fibrosis 
Y Feng, et 
al [81] 
Saphenous vein-derived pericyte 
progenitor cells (SVPs) 
miR-132 Inhibit Ras-GTPase 
activating protein and 
methyl-CpG-binding 
protein 2 
Improve 
contractility, 
reparative 
angiogenesis, and 
interstitial fibrosis  
Katare R, et 
al [82] 
 
Compared with liposomes, EVs have the following characters. 1) EVs contain a lipid layer 
and have a better fluidity; 2) membrane proteins contained in the lipid layer of EVs are 
potentially targeted; 3) EVs can be modified to carry the required membrane fusion and 
cell-uptake devices; 4) EVs are similar to the body’s own cells, so they are non- immunogenic 
and biocompatible; and 5) EVs are self-cell products which can avoid being degraded by 
macrophages, endosomal and lysosomal pathways. These natural features make EVs easier to 
be captured by target cells and enhance drug delivery efficiency, opening up new ways for 
drug delivery. However, there is still a long way to fully master physiological characteristics 
of EVs and improve EVs isolation and drug loading techniques, finally realizing the changes 
from basic to clinical practice. 
 
4. Nanoparticles used as diagnostics and biomarker for CVD 
 
Nanoparticles are increasingly being recognized as markers of disease presence and prognosis 
like cancer and cardiovascular diseases [83, 84]. Previously noted, EVs are produced by 
budding from cytoplasm. Therefore, their contents indirectly reflect the type and condition of 
original cells. By detecting EVs in the serum, urine and other bodily fluids, we may identify 
the disease presence and evaluate prognosis. For instance, hypoxia and oxidative stress altered 
the proteomic and RNA content of endothelial and mast cells [85]. Increased microvesicle 
levels were found in acute coronary syndrome than that in-stable angina [84]. Some clinical 
research suggested that plasma levels of exosomes subtypes might be used as indicators of 
vascular endothelium damage in CVD，but more work needed in exploring the potential and 
attractive ability of EVs.  
 
5. Engineering precision nanoparticles for personalized cardiovascular diseases 
 
Current efforts in nanoparticle work develop increasingly towards tailored approaches and for 
this purpose nanoparticles, including extracellular vesicle therapy for heart disease, are being 
modified more and more, such as Enzyme Prodrug Therapy (EPT) and Microfluidic 
technology. EPT makes it possible to release drugs in desired positions by converting inactive 
prodrugs to active drugs with the participation of enzymes [86]. Microfluidic extrusion 
approaches for fabricating exosome mimetics from donor cells and microfluidic surface 
engineering of living-cell-derived exosomes are two research direction in microfluidic 
technology, but still face lots of challenges [87]. Magnetically sensitive microcapsules have 
provided a novel method of targeted cell delivery. Magnetically sensitive cells which contain 
magnetic nanoparticles in their walls can transfer to the desired sites and repair the damaged 
tissue in applied magnetic field [88]. However, there is almost no research on the application 
of magnetic sensitive microcapsules to cardiovascular diseases. 
 
6. Conclusion 
 
Cardiovascular disease (CVD) is one of the leading causes for death. Although great advances 
of therapy strategies have been achieved in acute myocardial infarction in recent years, 
pathological ventricular remodeling often causes survivors to suffer from fatal heart failure. 
Nanoparticles as emerging drug delivery vehicles are drawing more and more attention, 
especially in cardiovascular areas. In this review, we summarized current knowledge about 
nanomedicine for post-infarct ventricular remodeling, and described basic mechanisms of 
ventricular remodeling, including hypertrophy, fibrosis, inflammation, mitochondrial 
dysfunction, autophagy and apoptosis. A better understanding of the mechanisms would help 
us to find new therapeutic targets for ventricular remodeling. We also listed potential 
nano-cargo such as drugs, proteins and RNA for post-infarct ventricular remodeling. Once 
nanoparticulated, these drugs, proteins and RNA might have a better cardioprotective effects. 
Furthermore, we summarized the characters of inorganic nanoparticles, liposomes and 
extracellular vesicles and listed their application in post-infarct ventricular remodeling. 
Nanoparticle-based drug delivery system shows high compatibility, low toxicity, high drug 
accumulation and controllable drug release. To broaden the knowledge about nanomedicine, 
we also briefly described engineering of nanoparticles.   
 
7. Future Perspective 
 
To date, nanoparticles packed with peptides, siRNA and other small molecules are observed to 
exert beneficial effects on damaged cardiac myocytes and the infarcted heart both in vitro and 
in vivo. What’s more, nanoparticles are shown to be potential biomarkers of CVD. 
Nonetheless, there are still some problems in the application of nanoparticles for treating 
post-infarct ventricular remodeling: 1) Nanoparticles are lack of specific markers on targeting 
cardiac myocytes. It can cause drug accumulation in other relevant target organs and 
correspondingly produce toxic and side effects. 2) The study of nanoparticles for improving 
cardiac remodeling is lack of the combination of long-term and short-term animal 
experiments. The commonly accepted method for establishing the model of AMI in rats is left 
anterior descending artery ligation. The surgery is very demanding on the operator's skill and 
is extremely traumatic for rats. Therefore, the long-term survival rate of rats (more than three 
weeks) is quite low. The future work should emphasize on the long-term animal experiments 
and investigate the long-term effects of nanoparticles to the infarcted animals. 3) There are 
few studies on the effects of nanoparticles on ion channels in cardiac myocytes. The ion 
channel is a popular and challenging topic in cardiac research. Do nanoparticles affect the ion 
channels in cardiac myocytes? If yes, what is the mechanism? This may be a direction for 
future research on nanoparticles. 4) There is still great technical difficulty and cost concerns 
in the ideal combination of drugs and nanoparticles. The nanoparticles need to be well 
engineered to achieve desired size, shape, surface charge, and other physicochemical 
properties, thus a complex and costly method are demanded. Incomplete characterization of 
nanoparticles can lead to various biological effects. In addition, materials with combination of 
less toxicity and side effects, better biocompatibility, and more controllable drug release will 
pose major challenges to the materials industry. 5) Nanoparticles for the treatment of 
post-infarct ventricular remodeling are still lacking clinical data. Current research in this area 
is still limited to animal and cell experiments and there are no reliable clinical trials to support 
the idea. More work is urgently needed to achieve clinical transition of nanoparticles. 6) 3D 
printing has gained a significant focus in biomedical and nanobiomaterials research. Future 
studies may adopt 3D printing technology in nanoparticle-based drug delivery system. 
 
On a positive note, nanoparticles as the delivery vehicle of various drugs have already entered 
clinical research for the treatment of hepatic fibrosis and cancer. This brings hope to 
nanoparticles for post-infarct ventricular remodeling. 
 Executive Summary 
Introduction 
· The prevalence of heart failure is gradually increasing and ventricular remodeling is the         
major cause. 
· Nanoparticles have great potential as drug delivery vehicles in post-infarct ventricular 
remodeling. 
The mechanism of ventricular remodeling 
·  Hypertrophy, fibrosis, inflammation, mitochondrial dysfunction, autophagy and 
apoptosis are the basic mechanisms of ventricular remodeling. 
Nano-cargo for ventricular remodeling  
·Nanoparticulation of drugs, proteins and RNA is expected to treating post-infarct 
ventricular remodeling.  
Nanoparticles for treatment of post-infarct ventricular remodeling 
· Inorganic nanoparticles, liposomes and extracellular vesicles as delivery vehicles of 
RNA, protein, drugs，et al, have been studied in basic research in the treatment of 
post-infarct ventricular remodeling.   
Nanoparticles used as diagnostics and biomarker for CVD 
· Nanoparticles are increasingly being recognized as markers of presence and prognosis of 
cardiovascular diseases. 
Engineering precision nanoparticles for personalized cardiovascular diseases 
· Enzyme Prodrug Therapy (EPT) and Microfluidic technology increase the precision of  
   targeting. 
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